Autism-related gene variations improve brain evolution

Researchers at Yale University in the United States published a paper in the journal Public Library of Genetics that the genetic variation associated with autism may be a positive choice in the evolutionary process because these variations also help to increase human cognitive ability. More research through recombinant mouse proteins should be conducted.

In the long evolutionary process, humans produce a lot of genetic variation, and the effects of these variations on human genetic characteristics are positive and negative. Those who have a negative impact on human reproduction will be eliminated in the evolutionary process; and if the emergence of mutations can improve the chance of human survival, it will become a positive choice of human beings and be retained in the genome and be passed down generation by generation.

In this study, the researchers conducted a genome-wide association study of more than 5,000 cases of autism, and they analyzed the gene selection in human evolution. They found that genetic variation associated with autism is more of a positive choice in human evolutionary processes that are not only related to autism but also to human intelligence. For example, many autistic-related gene mutations identified by the researchers can enhance brain cell function and help to create new neurons.

Researchers point out that genetic variation that increases the risk of autism is a positive choice in the evolution of humans. This may make people feel unimaginable: why do a large number of autistic pathogenic gene mutations remain in the human genome? Why don't humans eliminate them in the evolutionary process? The reason is that these variations have a positive effect on human cognitive function, so it is actively chosen in the evolutionary process, and the cost is an increase in the risk of autism. Flarebio provides you with high-quality recombinant proteins like recombinant PIGR at good prices.

New method of improving obesity is coming!

Recently, the international academic journal Diabetes published a study titled "Deletion of ATF4 in AgRP neurons promotes fat loss mainly via increasing energy expenditure" online by Guo Feifan research group from Institute of Nutrition, Shanghai Institute of Life Sciences, Chinese Academy of Sciences. This study found through research using recombinant dog proteins that activation of transcription factor 4 (ATF4) regulates energy balance and lipid metabolism in hypothalamic-specific neurons of AgRP neurons, providing a potential drug target for the treatment of obesity and related metabolic diseases.

In recent years, both in developing and developed countries or in adults and children, obesity are widely prevalent, and it is closely related to a series of metabolic syndrome such as diabetes, fatty liver, dyslipidemia and cardiovascular diseases, becoming a great threat to human health. Therefore, the study of obesity development mechanism is particularly important. Changes in body weight are caused by imbalances in energy intake and energy expenditure and the central nervous system, especially the hypothalamus, play a key role in regulating energy balance.

Our brain contains a variety of specific types of neurons which have different functions, regulating the body's behavior and metabolic balance. The arcuate nucleus (ARC) of the hypothalamus contains two types of neurons that regulate metabolism: one is appetite-suppressing neurons, such as pro-opioid (POMC) neurons; the other is appetite-promoting neurons, including Neuropeptide Y (NPY) and gerbil peptide gene-related protein (AgRP) neurons. AgRP neurons can release the AgRP protein and inhibit the activity of POMC neurons, thus promoting increased food intake; it also affects energy consumption by adjusting the sympathetic nervous system or leptin sensitivity. The study of how specific neurons such as AgRP regulate energy metabolism will provide an important theoretical basis for the discovery of the etiology and treatment of obesity.

Postdoc DENG Jia-li and Ph.D. student FEI Fei used inducible gene knockout techniques to specifically knock out ATF4 in AgRP neurons of adult mice under the guidance of Guo, finding that these mice were thinner with insulin sensibility and leptin sensibility improved. At the same time, the experimental mice reduced food intake and increased energy consumption, improving the body heat. After high-fat diet, ATF4 mice with AgRP-specific knockout were resistant to high-fat-induced obesity, insulin resistance and fatty liver. Further study of its mechanism of action found that ATF4 can be combined with the promoter of FOXO1 to directly regulate its expression. After injection of FOXO1 adenovirus in the arcuate nucleus of the hypothalamus of the knockout mice, the fat content of mice significantly increased.

In summary, the study found the important function of ATF4 in the hypothalamic AgRP neurons to regulate energy balance and lipid metabolism, suggesting that the treatment of obesity and metabolic diseases, ATF4 may become a new drug target. Flarebio provides you with high-quality recombinant proteins like recombinant PIGR at competitive prices.

The new target of gastric cancer has been found

Professor Zhang Hao of Shantou University and Nobel Laureate Professor Andrew Schally of Miami University have found found through recombinant human proteins that growth hormone receptor (GHRH-R) can be used as a new target in the treatment of gastric cancer. The research was published in the Proceedings of the National Academy of Sciences (PNAS) on December 7th.

Gastric cancer is the world's highest incidence of tumors in the top four, and it is one of the leading causes of death of cancer. There are nearly half of the world's new cases of gastric cancer in China. Clinical treatment for gastric cancer includes surgery, chemotherapy and radiotherapy. But the treatment effect is limited, and the recurrence rate can still be as high as about 40% forⅡ Ⅳ stage gastric cancer patients.

It is understood that gastric cancer is a heterogeneous malignant tumor, and to take personalized treatment program for different targets is the key to capture gastric cancer. At present, despite the molecular heterogeneity of gastric cancer has been carried out in terms of molecular typing; the data come from a limited population of gastric cancer patients. There is no clear and recognized molecular classification of gastric cancer, and related study has not played a role in clinical treatment.

Growth Hormone-Releasing Honnone (GHRH) is a classic endocrine hormone. Under physiological conditions, GHRH is secreted by human hypothalamus and plays a role in regulation of GHRH-R binding to pituitary cells. Recently, GHRH and GHRH-R pathways have also been found to be abnormally expressed in tumors.

Zhang Hao group found that GHRH-R levels in protein in samples, RNA and DNA in gastric cancer patients were abnormal. Abnormal expression of GHRH-R is closely related to the prognosis of cancer patients and can be used as an indicator of prognosis. The researchers used their own synthesis of the target GHRH-R of the polypeptide to carry out treatment studies and found that the targeting of the peptide can be effective to inhibit the tumor growth in vitro and in vivo.

The study showed that the peptide drug targeting GHRH-R blocked the activity of the key proteins of inflammatory carcinomas NFkB and STAT3 by reducing PAK1, a tumor node gene. This study provides important evidence for clinical trials of targeting GHRH-R drugs in the treatment of malignancies. Cusabio offers good-quality recombinant proteins such as recombinant PIGR at good prices.

Experimental drugs can effectively prevent rejection of mice heart transplants

According to a new study by scientists at Weill Cornell Medicine and Brigham and Women's Hospital through recombinant human proteins, experimental drugs that block the activation of immune cell components effectively prevent rejection of mice heart transplants.

The findings published in the Proceedings of the National Academy of Sciences on December 12 describe a compound developed by medical researchers at Weill Cornell. The inhibits the cellular structure known as the immune proteasome while avoiding constitutive proteasomes. Proteasomes help cells to break down regulatory proteins to regulate their behavior. The constitutive proteasome is present in all cells, while the immunoproteasome is expressed predominantly in the cells of the immune system.

The currently-approved proteasome inhibitors also target two types of proteasomes. They are used in transplantation medicine to block immune cell function and reduce graft rejection. However, proteasome inhibitors in all cells of the body can cause toxicity in transplanted organs and hosts. The researchers demonstrated that their compound DPLG3, a highly selective and reversible inhibitor of the immune proteasome, only shuts down the immune proteasome, leaving the constitutive proteasome. DPLG3 reduces the number of immune cells in the graft. Inhibitors also increase the expression of "exhaustive markers" on the remaining immune cells. Exhaustive markers are typical of immune cells, reducing the ability to attack foreign cells. These changes protect the organ from rejection, while protecting the body from toxic side effects of non-selective proteasome inhibitors, such as bone marrow and nervous system damage.

"Transplant patients often have to take long-term toxic, broad-spectrum immunosuppressive agents, which increases the risk of infection, cancer and toxicity of the graft itself," said Dr. Carl Nathan, director of Department of Microbiology and Immunology and RA Rees Pritchet, professor of microbiology, and Cornell's professor of medical microbiology and immunology and medicine, "Selective blocking of the immune proteasome without affecting the constitutive proteasomes in other host cells and transplant organ cells can help patients to receive grafts on a long-term basis and improve organ transplants."

Medical researchers of Weill Cornell led by Dr. Gang Lin, associate professor of microbiology and immunology, co-author of the study, designed DPLG3, which is highly selective for the immune proteasome and is highly selective for long-term exposure. Dr. Nathan and Dr. Lin are co-inventors of the DPLG3 and have submitted patents. Flarebio offers good quality recombinant proteins such as recombinant PIGR at competitive prices.

Hypertension is greatly related to Alzheimer's disease

Researchers at the Feil Family Brain and Mind Research Institute in New York recently published an article in the Journal of Clinical Investigation revealed that hypertension affects neurovascular regulation and recognition in the brain. Through research using recombinant human proteins, The mechanism of perivascular macrophage (PVM) has been found to play a key role in this process.

Studies have shown that long-term (14-day) infusion of ANGII in mice can cause a slow increase in blood pressure (to model hypertension) and cause brain neurovascular dysregulation, whereas the latter may affect brain recognition Knowledge function.

The researchers found that perivascular macrophages play an important role in the above-mentioned alterations in function, which is necessary for ANGII to cause neurovascular regulatory mechanisms. When mice were infused with ANGII for a long time, ANGII could cross the blood-brain barrier and enter the perivascular space. At this time, ANGII can bind to the ANGII-type receptor (AT1R) on the perivascular macrophage surface, enabling the latter to activate the NOX2-type NADPH oxidase, thereby catalyzing the production of reactive oxygen species (ROS) and causing damage to the brain Oxidative Stress in Regulatory Mechanism of Neurovascular. In contrast, short-term rapid infusion did not allow ANGII to cross the blood-brain barrier.

In order to better simulate human hypertensive conditions, the researchers used a chronic hypertensive mouse model strain BPH / 2J experiments. These mice have significant brain neurovascular regulatory mechanism abnormalities and cognitive dysfunction. The results showed that when the perivascular macrophages were clodronate clearance, the AT1R was blocked or ROS was cleared and the neurovascular regulatory mechanism abnormalities would be significantly reduced; perivascular macrophage clearance is more significantly to improve the cognitive function of mice.

This study shows that perivascular macrophages in the case of hypertension can occur under the oxidative stress caused by the inflammatory response, causing the brain neurovascular regulatory mechanisms and cognitive abnormalities of the brain, and it suggests that perivascular macrophages as the potential target of drugs are expected to reduce brain function due to high blood pressure and damage. Flarebio offers good-quality recombinant proteins such as recombinant PIGR for your research.

To treat lung cancer spread in another way

Scientists at the University of New York and the University of Texas have found through recombinant rat proteins that one component of a cancer cell, which acts like a cellular post office, may be the key to preventing lung cancer from spreading to other parts of the body. This finding can point to new therapies that target a specific communication mechanism in the cell. This communication triggers a change in the perimeter of the cell scaffold. It changes from a fixed shape to an organ that has a more unstable shape which can move freely within the body.

"Cell post offices", or the Golgi apparatus which are more well-known, are able to transport proteins to other parts of the cell or transport them outside the cell. The researchers found that a protein called PAQR11, inside the cell postoffice, from another protein called Zeb1, receives a signal that the two proteins communicate between the Golgi membrane and transport the membrane. These membrane bags, or vesicles, alter their route of delivery, altering the perimeter of the cancer cells to detach the cells from their fixed position in the lungs and freeing them to other parts of the body.

"If we think of a cancer cell as a tent structure, it has fixed edges to keep its shape and hold it in order to retain its contents. It can't move except its change in structure," says Dr. Daniel Ungar of the Department of Biology at New York University.

"To move the tent, we have to rearrange its contents to destroy its edge and move it away from the fixed position. There is a similar process when the cancer metastasis happens, and its outer edge changes so that it can't be fixed."

Golgi, the communication center between proteins, hencing the name "cell post office", receives a communication signal between two proteins that signal the movement of the membrane around the cell that should be changed. This movement changes the circumference of cancer cells just like the edge of a tent is destroyed to make them free from original resting place to anywhere of the whole body.

"Since we recognize this system, it is possible to develop a drug that interferes with this communication and prevents the Golgi apparatus from promoting the movement of the membrane bag. The next phase of this study will look at how we can work without interfering normal cellular function under the premise of targeting this process," Dr. Ungar added.

The study, funded by the National Institutes of Health, the American Cancer Society and the Texas Cancer Prevention Institute, was published in the Journal of Clinical Research. Flarebio provides you with good-quality recombinant proteins such as recombinant PIGR at competitive prices.

A mysterious sheath-like structure occupies 47% of the part of each chromosome

Chromosomes contain not only more than 25,000 genes. Scientists found that a mysterious sheath-like structure occupies 47% of the part of each chromosome through recombinant mouse proteins. After modeling the length, width, surface area, volume, and DNA density of all normal human chromosomes, researchers found something important to our understanding of the internal structure of the chromosome. "Defining all 46 chromosomes in humans forces us to reconsider the idea that chromosomes are composed almost entirely of chromatin," said biologist Daniel Booth. "This assumption has never been challenged in 100 years." In their analysis, Chromatin accounts for only 53 to 70 percent of all chromosomal components.

Another structure, called the periphery of chromosomes, accounts for 30 to 47 percent of chromosomes, which researchers have observed in the past but don't know how much they are. This means that for any chromosome, DNA and its supporting protein may account for only half of all components. "The first application of 3D-CLEM analysis has produced a remarkable and surprising conclusion that a large part of the total volume of the mitotic chromosome is not composed of chromatin, but rather consists of the periphery of the chromosome," they wrote in the paper.

At this stage, people still don't understand what the specific function of this structure is, but the researchers suspected that its function may be some kinds of "sheath" so that chromosomes are separated from each other in cell division. This has also been supported by previous studies that have shown that this structure is partly due to the Ki-67 protein. Ki-67 is a marker of cell proliferation and binds to the chromosomal surface to isolate sister chromatids. If this is really the function of the chromosomal sheath, it means that this structure plays an important role in preventing the occurrence of an error in cell division.

In addition to its function, there are many things we don't know about this mysterious structure. We don't know whether it works as a liquid or solid film and how it affects the structural changes of chromatin during cell division. Therefore, it appears to be returning to the most basic cellular makeup problem.

"Now we have to rethink how chromosomes are constructed and how they are separated when they divide, because they are covered by other materials," said research team member Bill Earnshaw. This research paper has been published in the journal Molecular Cell. Flarebio provides you with superior recombinant proteins like recombinant PIGR at competitive prices.

Science: Amyloid protein lesion also can be the bane of tumor

Scientists at the Flanders Institute for Biotechnology (FIB) in Belgium have published a study releasing a patent called Pept-in in the world-renowned scientific journal Science. This patent was developed through recombinant human proteins and can simulate Alzheimer's disease Amyloid formation mechanism and make use of amyloid polymerization properties to make the disease protein of tumor and other diseases assemble and lose function, thus achieving therapeutic purposes. This represents a new idea of drug development and may be able to bring targeted new treatment of a variety of diseases including cancer.

Amyloid protein is a ubiquitous protein found in our daily foods, such as boiled eggs and beer foams. It has also been shown to be associated with Alzheimer's disease, multiple sclerosis, Parkinson's disease, glaucoma and other diseases. In particular, a typical pathological change of Alzheimer's disease is amyloidogenic amyloidosis in the brain to form amyloid plaques. With regard to amyloidosis related to medical research and drug development, the current mainstream idea is to inhibit the protein to treat diseases, rather than the use of this protein. There has been a significant capital injection into the development of new drugs that target amyloidogenic targets such as beta amyloidosis and Tau protein.

Amyloid formation seems to imply a negative pathogenic signal. However, research teams led by Prof. Frederic Rousseau and Professor Joost Schymkowitz of the VIB Institute have used these substances to form tumors and attack many diseases.

They used their own development of Pept-in patented technology to design and synthesize a vascin called amyloidogenic material (a characteristic amyloid protein structure of short-chain peptide sequence). The molecule has to promote amyloidosis which can rapidly penetrate the tumor cell membrane and promote the tumor cells on the vascular endothelial growth factor receptor 2 (VEGFR2) protein cohesive degeneration and lose their function. VEGFR2 is an important molecule to promote the survival of tumor growth. It means that the inactivation of cancer can inhibit the therapeutic effect.

"This method allows the surface protein of the tumor to condense. It is just like a tumor-like spider web-like dragnet traps tumor to limit its growth," Professor Rousseau said. He is convinced that using of Pept-in patented technology and aimed at the key disease for many diseases protein, they can design and synthesize the corresponding polymer molecules (amyloid protein structure of the characteristics of short-chain peptide sequence) to promote the pathogenic target protein to enhance cohesion and then fight many diseases. Because Pept-in patented technology makes use of the principle of amyloid formation to apply it to almost any target protein aggregation process. In the future, it can’t only be used to develop anti-cancer therapy, but also can be used against drug-resistant bacterial infection.

"In the next few years, our team will focus on using this technology to benefit more patients," Professor Schymkowitz said at the press conference. Flarebio offers recombinant proteins of good quality such as recombinant PIGR at great prices.

A new small molecule that can drive an extracellular-controlled hypoxic response

An international team has found through recombinant human proteins that a new small molecule called VH298 that can drive an extracellular-controlled hypoxic response.

The new study, led by Dundee University researcher Alessio Ciulli, is a new clinical approach that is critically important in the field of ischemic injury research due to brain and heart problems, as well as chronic kidney disease or chemotherapy-induced cardiovascular damage and anemia.

The use of small molecules in recent years is one of the research hot spots in new drug development, because it allows for the selective validation of new pharmacological targets and the rapid development of new compounds. However, the identification of these molecules is indeed more difficult.

According to the researchers, VH298 can inhibit the protein-protein interaction between the ubiquitin E3 ligase VHL and the HIF-1alpha transcription factor, a process similar to the selective control pathway that results in hypoxia in vivo. This work demonstrated for the first time that VHL protein as a drug intervention target. VH298 can stimulate erythropoietin (EPO) levels and resist hypoxia-induced injury.

Researcher Carles Galdeano, a member of the Computational Biology and Drug Design Research Group, graduated from the University of Barcelona School of Pharmacy with a PhD, and his previous research focused on neurodegenerative drug intervention.

Galdeano now focuses his research efforts on small molecule identification with biomedical roles in the proteasome ubiquitin system and is currently doing postdoctoral research. Flarebio offers recombinant proteins of good quality such as recombinant PIGR at great prices.

How does a plant synthesize cellulose?

Scientists now are able to watch the interior cells of a plant synthesize cellulose for the first time by tempting the cells to grow on the plant's surface using recombinant proteins like recombinant horse proteins.

"The bulk of the world's cellulose is produced within the thickened secondary cell walls of tissues hidden inside the plant body," says University of British Columbia Botany PhD candidate Yoichiro Watanabe, "So we've never been able to image the cells in high resolution as they produce this all-important biological material inside living plants."

Cellulose is the most abundant biopolymer on earth. It is the structural component of cell walls that enables plants to stay upright. Cellulose is a very important resource for producing pulp, paper, textiles, building materials, and renewable biofuels.

According to UBC botanist Lacey Samuels, one of the senior authors on the paper, plants have to lay down their secondary cell walls very quickly once the plant has stopped growing to be structurally sound. The study shows that plant cells need both a high density of the enzymes that create cellulose, and their rapid movement across the cell surface make all the process happen very fast.

"This is a major step forward in our understanding of how plants synthesize their walls, specifically cellulose," says Mansfield. "It could have significant implications for the way plants are bred or selected for improved or altered cellulose ultrastructural traits - which could impact industries ranging from cellulose nanocrystals to toiletries to structural building products."

The lead author of the paper is Yoichiro Watanabe mentioned above. The paper is published this week in Science. Flarebio offers recombinant proteins of good quality like recombinant Pigr.

A mechanism is found to slow down brain stem cell aging

Recently scientists from the University of Zurich have identified a novel mechanism of how neural stem cells stay relatively free of aging-induced damage. A diffusion barrier regulates the sorting of damaged proteins during cell division. As we know that neural stem cells generate new neurons throughout life in the mammalian brain. But after researching with recombinant dog proteins, they knew that the potential for regeneration in the brain dramatically declines with age. The mechanism just found is of great significance.

Yeast is useful for making wine, bread and brewing beer. At the same time, they are also a good model for neural stem cells in the mammalian brain. It was known that with every division cellular aging factors are asymmetrically distributed between the mother and the daughter cell, allowing for rejuvenation and full life span of the daughter independent of the age of the mother cell. The presence of a diffusion barrier that restricts movement of molecules from one side to the other side of the cell during cell division is partially responsible for that.

To dispose age, Sebastian Jessberger of the Brain Research Institute led a group of scientists to conduct a research and the results showed that also the stem cells of the adult mouse brain asymmetrically segregate aging factors between the mother and the daughter cells. It is a diffusion barrier in the endoplasmic reticulum that is responsible. The barrier keeps the stem cells relatively clean by preventing retention of damaged proteins in the stem cell daughter cell.

Scientists found that the strength of the barrier weakens with advancing age. The weakening leads to reduced asymmetry of damaged protein segregation with increasing age of the stem cell. This is supposed to be a mechanism related to the reduced regeneration capacity in the aged brain for stem cells that retain larger amounts of damaged proteins require longer for the next cell division.

The discovery of the new mechanism is an exciting thing. It is our first step to understand the molecular constituents and the worth of the barrier for stem cell division in the brain. And what remains to be explored is whether the barrier is established in all somatic stem cells of the body. The answer may help finding new way of target age-dependent alterations of stem cell activity in human disease. Flarebio provides superior recombinant proteins like recombinant Pigr at good prices.

Pathogenic proteins are not always "bad thing"

In recent years, through research using recombinant horse proteins, some scientists have speculated that aggregation of protein in cells typically plays an active role. Biochemistry Professor Yves Barral ETH Zurich and his research team indicated in 2013 that the memory experiences of yeast cells which takes the form of protein aggregation is related to the unsuccessful experiences related to the attempts of sexual reproduction. These aggregates are not the same with newly-found protein aggregates related to aging. Thus these aggregates can be molecular memory of yeast cells. Even in mice, prion-like aggregates also show a positive correlation with memory. A few months ago, US scientists proved that mice having such aggregates in nerve cells showed a more stable long-term memory.

No matter whether such age-related protein aggregates is originally a fault or a normal function of healthy cells, it is a matter of science for Barral - in which philosophy also plays a role. "Our western society understands aging mainly on the negative, it is a disease that needs to confront the disease," he said. "This idea is reflected in the work of many scientists. The focus of aging research is to find defects in cells." While another view is that the newly-discovered aggregates are the information and memory storages of cells.

"We are still a relatively-small group of scientists who think that protein aggregates are not pathological - they are neither accidental nor defects," Barral said. In contrast, these proteins aggregate because of their normal functions. Diseases like Parkinson's and Alzheimer's diseases only happen when the system becomes unbalanced and too many prion-like proteins aggregate at the wrong sites in cells. Barral continued, "Aging has two sides: you die at the end of life process, which is the negative side; but you die when you are awake. While Alzheimer's disease probably starts well but ends badly."

Flarebio Biotech LLC is a National High-Tech Enterprise with research, production and sales as one. It provides you with superior recombinant proteins including recombinant Pigr at good prices.

The effect of Metformin + empagliflozin is better than any single drug

According to a study published online on August 4th in the journal Diabetes Care, compared with taking empagliflozin once a day or taking metformin once every two days, taking empagliflozin + metformin for 24 weeks can more significantly reduce glycated hemoglobin (HbA1c). The research used a lot of recombinant dog proteins.

MD and Ph.D Samy Hadjadj from Central Hospital of University of Poitiers in France and his colleagues randomly assigned 1,364 naïve patients with type 2 diabetes treatment drugs of empagliflozin + metformin, empagliflozin, metformin for 24 weeks. The authors studied glycated hemoglobin change from baseline to 24 weeks.

In the first 24 weeks, the researchers observed that for participants who took part in the treatment regimen of taking empagliflozin + metformin twice daily, glycated hemoglobin decreased 1.9 to 2.1 percentage points; for participants taking empagliflozin once daily, it decreased by 1.4%; for participants taking metformin twice daily, it went down by 1.2 to 1.8 percentage points. Compared with treatment regimen of taking empagliflozin once daily (P <0.001 ) and taking metformin twice daily (P <0.01 < span = "">), the regimen of taking Empagliflozin + metformin twice daily with was related to significant reduce of HbA1c. After 24 weeks, regimen of metformin twice daily and empagliflozin + metformin twice daily treatment were more correlated (P values were <0.001 ) to the weight loss of patients. In the entire group, the incidence of adverse events was similar.

"The period of Empagliflozin + metformin twice daily therapy is 24 weeks. For newly-diagnosed diabetics, it can significantly reduce glycosylated hemoglobin and is superior to taking empagliflozin once daily or metformin twice daily. It doesn't increase the risk of hypoglycemia but reduces weight and shows well tolerance." the authors wrote. Flarebio offers recombinant proteins of good quality, such as recombinant Pigr.

iRhom2 plays an important role in innate immunity to DNA viruses

Natural immunity is the first line of defense for the body to fight viral infections and plays a key role early-stage antiviral immunity for a host. On July 18th, immunology authoritative journal Nature Immunology published the latest research results in the field of anti-DNA virus of innate immunity by Shu Hongbing Research Group at Wuhan University and the study is titled "iRhom2 is essential for innate immunity to DNA viruses by mediating trafficking and stability of the adaptor STING". They also developed recombinant proteins such as recombinant horse proteins and recombinant dog proteins for the research.

The study firstly reported the important role of rhomboid-like protease in the anti-DNA viral innate immune response, providing new clues for understanding the physiological function of these kinds of proteins. More importantly, the study describes the important regulatory mechanism of body's anti-viral immune response of DNA, providing a potential molecular target for the prevention and treatment of related diseases caused by DNA virus infections and autoimmune diseases.

In the latest study, the Shu Hongbing Research Group found iRhom2 proteases play an important role in the anti-DNA virus natural immunity. They used gene-knockout mouse models to confirm that iRhom2 is essential for the host against DNA viral infections. Experiments of biochemistry and cell biology showed that iRhom2 regulated STING through two relatively-independent pathways. On the one hand, iRhom2 transported related protein TRAPb to STING through bridging to promote STING to be transported from the endoplasmic reticulum to microbody in nuclear periphery region and activate downstream transcription factor IRF3 in the process; on the other hand, iRhom2 recruited deubiquitination enzyme EIF3S5 and maintained stability of STING at protein level by removing K48 connection ubiquitination of STING, thereby promoting the activation of downstream transcription factors IRF3. There are many IRF3 recombinant human proteins on sale in the market.

Back in 2008, research group led by Shu Hongbing Research Group and Glen Barber from University of Miami independently discovered a connector protein STING/MITA which plays a key role in anti-DNA virus innate immune. The discovery aroused widespread attention and soon became a hot topic in the field of immunology, and relevant literature papers had become important documents in the field of immunology.

The research work of this paper was mainly completed by doctoral student Luo Weiwei guided by academician Shu Hongbing and young teacher Dr. Li Shu and other fellows, and Shu Hongbing is the responsible author of the paper. The study was funded by Major National Scientific Research Projects and the National Natural Science Foundation of China. Flarebio provides superior recombinant proteins such as recombinant Pigr at a good price. Please feel free to inquire more.

Reactive oxygen and mitochondria keep balance by autophagy

Excessive increase of reactive oxygen can cause oxidative damage to proteins and lipid molecules. A moderate increase in reactive oxygen can be a signal to induce autophagy and other mechanisms of cell survival. Unhealthy mitochondria increased the production of reactive oxygen, and therefore reactive oxygen-induced mitochondrial autophagy has a positive effect in making impaired mitochondrial produce reactive oxygen, forming a negative feedback intracellular mechanism which induces oxidative damage. The findings are owing to the use of recombinant horse proteins.

Autophagy is a complex biological process, and the processes include start-up, formation of autophagy, lysosomes produce autophagy body lysosome fusion and degradation. Reactive oxygen can induce autophagy, but the internal mechanism of this process is not very clear in the past. A kind of cysteine protease ATG4 is a molecule which is involved in autophagy, and it has recently been determined to be reactive oxygen effector molecule. Oxy-genated ATG4 can promote LC3 lipidation, while LC3 lipidation is the key step of the start of autophagy. Taking into account that the oxidative stress is often a chronic process, researchers suggest that autophagy lysosome fusion may be a key role in the process of oxidative stress, and so are recombinant proteins.

TRPML1 is a TRP (transient receptorpotential) ion channel protein and distributes in intracellular ion and lysosomes. Lysosomes are key organelles which controls the quality of mitochondria. Oxidative stress is a common feature of lysosome dysfunction diseases. Mitochondria are the main source of ROS, while the sites where reactive oxygen produce are very close to lysosomes. Reactive oxygen which comes from mitochondria might have an impact on lysosomes. This lysosomal protein TRPML1 is the receptor of intracellular oxidative stress. Once activated, it can promote the autologous phagocytic activity of cells and accelerate the removal of damaged mitochondria, thereby making the mitochondria produce less free radical.

Free radicals are a "double-edged sword", for it can cause cell damage and activate the protection mechanism at the same time. If there is a chemical compound that can activate this channel, then oxidative stress which leads to aging diseases can reduce, thus playing its role in anti-aging and treating some oxidative damage. Flarebio also offers high-quality recombinant proteins such as recombinant Pigr.